Ebselen in Acute Ischemic Stroke


Phase N/A Results

Trial Description

To study the effect of ebselen on the outcome of acute ischemic stroke.


  • Ebselen (Harmokisane)Drug
    Intervention Desc: Antioxidant (seleno-organic compound with antioxidant activity through a glutathione peroxidase-like action)

Trial Design

Multicenter, placebo-controlled, double-blind clinical trial involving 300 patients.

Patient Involvement

Oral administration of ebselen granules suspended in water (150 mg BID) or placebo was started immediately after admission and was continued for 2 weeks.


Type Measure Time Frame Safety Issue
Primary Glasgow Outcome Scale scores at 1 month and 3 months after the start of treatment.
Secondary Modified Mathew Scale and modified Barthel Index scores at 1 month and 3 months.